Get the Stockscreener App
0.2004
0.20%
0.0004
After Hours:
.21
0.0096
+4.79%
China Pharma Holdings Inc. stock is traded at $0.2004, with a volume of 41,758.
It is up +0.20% in the last 24 hours and down -21.53% over the past month.
China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, cephalosporin oral solutions, and granules. The company's products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Anhydroandrographolide for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; and Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. is headquartered in Haikou, the People's Republic of China.
See More
Previous Close:
$0.20
Open:
$0.204
24h Volume:
41,758
Relative Volume:
0.11
Market Cap:
$3.86M
Revenue:
$5.54M
Net Income/Loss:
$-4.74M
P/E Ratio:
-0.4175
EPS:
-0.48
Net Cash Flow:
$-750.60K
1W Performance:
+4.10%
1M Performance:
-21.53%
6M Performance:
-33.20%
1Y Performance:
-69.15%
1-Day Range:
$0.1943
$0.204
1-Week Range:
$0.1841
$0.205
52-Week Range:
$0.17
$0.744
China Pharma Holdings Inc. Stock (CPHI) Company Profile
Name
China Pharma Holdings Inc.
Sector
Phone
86 898 6681 1730
Address
No. 17, Jinpan Road, Second Floor, Haikou
Compare CPHI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CPHI
China Pharma Holdings Inc.
|
0.2004 | 3.86M | 5.54M | -4.74M | -750.60K | -0.336 |
|
ZTS
Zoetis Inc
|
175.25 | 79.07B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.66 | 43.68B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.62 | 43.18B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.78 | 19.01B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
13.09 | 15.62B | 15.05B | -883.30M | 1.89B | -0.74 |
China Pharma Holdings Inc. Stock (CPHI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-10 | Initiated | Rodman & Renshaw | Mkt Outperform |
China Pharma Holdings Inc. Stock (CPHI) Latest News
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Stock market news : Feishang Anthracite Resources surges 49.48% as Shanghai Jiaoda Withub gains 34.62% - Business Upturn
China Pharma (NYSE:CPHI) Coverage Initiated at StockNews.com - Defense World
China Resources Pharma Restructures for Industry Growth - MSN
Layoff Tracker: Sonata Therapeutics Laying Off 20 Employees, Changing Leadership - BioSpace
StockNews.com Begins Coverage on China Pharma (NYSE:CPHI) - Defense World
Biopharma Layoffs Roundup - Contract Pharma
Global Medical Tech Becton, Dickinson Expects Lower China Sales, Bioscience And Pharma Market Dynamics To Impact 2025 Organic Revenue Growth - Yahoo Finance
Pharma giant AstraZeneca says China chief detained - Yahoo Finance
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
China Pharma (NYSE:CPHI) Coverage Initiated by Analysts at StockNews.com - Defense World
5 Biggest Pharmaceutical ETFs in 2024 - Investing News Network
Exploring High Growth Tech Stocks Including Digital China Holdings And Two More - Yahoo Finance
Is Merck & Co., Inc. (MRK) the Best Pharma Stock to Buy Right Now? - Yahoo Finance
AstraZeneca says its China operations president under investigation - Reuters
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by China Universal Asset Management Co. Ltd. - MarketBeat
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules - Yahoo Finance
Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews
Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine Congress Europe 2024 - Yahoo Finance
RRJ Buys $150 Million Luye Bonds, First China Deal Since 2019 - BNN Bloomberg
Insiders of China Medical System Holdings Limited (HKG:867) must be disappointed as stock fell 4.7% after recent purchases - Simply Wall St
AI Redefines the Pharmaceuticals Wholesale and Distribution Market, Projected to Grow by USD 896.5 Billion from 2024-2028, Boosting Global Sales - The Malaysian Reserve
Several Insiders Invested In Mayne Pharma Group Flagging Positive News - Yahoo Finance Australia
PDD Holdings Inc. (PDD): A Rising Star Among the Most Promising Chinese Stocks - Yahoo Finance
China Pharma (NYSE:CPHI) Research Coverage Started at StockNews.com - Defense World
China Constipation Treatment Drug Industry Growth Factors, Applications, and Forecast by (2024-2034) - IndiaPolitics.com
China Pharma Holdings Inc. (CPHI) is a good investment, but the stock may be undervalued - US Post News
The Psychology of China Pharma Holdings Inc. Inc. (CPHI) Price Performance: Understanding Market Sentiment - The InvestChronicle
CK Life’s Yuen banks on Big Pharma experience to boost new drug success - South China Morning Post
WuXi AppTec Falls 17% After $500 Million Convertible Bond Sale - BNN Bloomberg
CPHI’s 52-Week Rollercoaster: From $0.17 to $1.21 – What’s Next for Investors? - The InvestChronicle
Analytical Overview: China Pharma Holdings Inc. (CPHI)’s Ratios Tell a Financial Story - The Dwinnex
China's WuXi explores sale of pharma operations as US restrictions loom, FT reports - Yahoo Finance
7 Best Chinese Stocks to Buy | Investing - U.S News & World Report Money
Check out these key findings about China Pharma Holdings Inc. (CPHI) - SETE News
PDD Holdings: China Stimulus Adds Rocket Fuel, Reiterate Buy - Seeking Alpha
LEO Pharma announces Enstilar NDA submission for plaque psoriasis in China - Yahoo Finance
Here's Why Yum China Holdings (YUMC) is a Strong Growth Stock - Yahoo Finance
CPHI’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
LEO Pharma Submits New Drug Application for Enstilar® for Adults with Plaque Psoriasis in China - Yahoo Finance
China's Bold Stimulus Measures: What It Means for Markets - Saxo Bank
Tonix Pharmaceuticals Announces Data Presentations on TNX-102 SL for Fibromyalgia at the 11th Global Conference on Pharmaceutics and Novel Drug Delivery Systems (PDDS 2024) - Yahoo Finance
CSPC Pharma taps R&D superstar in quest for new breakout drugs - Bamboo Works
Yum China Holdings, Inc. (YUMC): Analysts Are Bullish On This Undervalued Cyclical Stock Now - Yahoo Finance
Investing in China Pharma Holdings Inc. (CPHI) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News
China Pharma Holdings Inc.: Weathering Stock Market Storms with 4.04M Market Cap - The InvestChronicle
Big pharma eyes China ‘at forefront of GLP-1 revolution’ - BioWorld Online
US House Passes Bill to Blacklist Some China Biotech Firms - Yahoo Finance
Summit’s checkpoint inhibitor trumps Keytruda in lung cancer trial - Clinical Trials Arena
Plasma Fractionation Market Size to Expand Lucratively by 2031 - WhaTech
Stocks to Watch, Sep 6: Glenmark Pharma, Godfrey, Max Fin Svcs, Pidilite - Business Standard
China Pharma Holdings Inc. Stock (CPHI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):